Abstract 17P
Background
In Australia, Indigenous people are natives and custodians of land. The mortality risk is more than double in Indigenous breast cancer women as compared to non- Indigenous women but carries lower incidence risk. Between 2001 and 2010 Indigenous Western Australian women who developed breast cancer were four times more likely to die of the disease than non-Indigenous women of the same age. The data is scarce but many factors are being studied. The effect of remoteness on mortality of indigenous women still needed to be established. The aim is to analyse remoteness as a factor causing effect on survival in Indigenous breast cancer women.
Methods
The data is collected retrospectively from Western Australian cancer Registry mostly, among other sources. A cohort of 100 patients was selected from database including half of indigenous and half non-indigenous women (1:1). At time of writing, 37 Indigenous and 33 Non–Indigenous breast cancer women data was available. The data collected, to analyze the median survival time (months) of patients with respect to Distance (Metropolitan vs Rural) and Indigenous & Non-Indigenous status.
Results
In survival analysis, it has been observed that both indigenous and non-indigenous who live in metropolitan showed better 10 year survival ; 184 months while who were in rural area showed reduced median survival time 130 months and differences among them was found to be significant (p = 0.03), suggesting better survival was associated with patients who live in metropolitan area. However, on analyzing the survival of Indigenous patients with respect to distance, it wasn’t statistically significant (p = 0.19) but still showed higher median survival for patients living in metropolitan area (153 months) as compared to remote rural areas (110 months). Further analyzing indigenous breast cancer patients outcomes with respect to metro area (153 months), 1000km or less and greater then 1000km (87 months); higher survival benefit trend for patient’s living close to metro area.
Conclusions
The data suggest that the Indigenous breast cancer women have inferior survival outcomes with respect to distance from metropolitan area, highlighting a strong co-relation of remoteness and survival disadvantage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Khan, A. Redfern.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract